Trial Profile
Phase 1 Study of Sipuleucel-T and Ipilimumab in Combination for Advanced Prostate Cancer
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 07 Nov 2021
Price :
$35
*
At a glance
- Drugs Ipilimumab (Primary) ; Sipuleucel-T (Primary)
- Indications Prostate cancer
- Focus Pharmacodynamics
- 10 Feb 2018 Results assessing the outcome and survival of the 6 surviving men, presented at the 2018 Genitourinary Cancers Symposium.
- 23 Aug 2017 Status changed from active, no longer recruiting to completed.
- 02 Jun 2015 Results presented at the 51st Annual Meeting of the American Society of Clinical Oncology.